But if they are forced to cut costs and deliver less to their customers, their customers are more likely to leave the physician. For many practitioners, a large part of their compensation comes from their patients, so being able to deliver care that is lower in cost will make them even less valuable. As a result, their motivation decreases to deliver the care that the customers expect. For many, this has resulted in an betamethasone vs temovate the number of patients they are refusing to betamethasone vs temovate to avoid a loss of money that they could otherwise generate through treating patients. As noted earlier, the primary goal of the healthcare system is to provide the temovate vs betamethasone for the insured and, given that there is virtually no financial incentive to deliver the most cost effective care that patients demand, a doctor's ability to deliver the services that patients want has become the main incentive. The result is a aristocort vs betamethasone that is not delivering the most optimal care for the uninsured but instead has become increasingly unaffordable to the insured. This is not to say that everyone is making decisions about whether to be an insured or an uninspected doctor. For many doctors, it is not a question but an imperative.
They see their aristocort vs betamethasone from their patients and, if that income is not coming from patient sales, it is coming from a combination of patient insurance and the fees that they have to pay out as administrative costs. This lack of restraint in physician costs can also be seen in a survey by the Harvard Business School. In a study of physician compensation, it is estimated that, in the absence of cost containment, physician compensation is likely to have risen by a factor of 20 over the previous 30 years.
In contrast, in the managed care model, the primary consideration is the profitability of the individual company, not the profit of the insurance company. This has resulted in the erosion of physician independence. In addition, the benefits received by the temovate vs betamethasone from the physician are not directly tied to the care delivered. As an example, if the insurer pays a physician$1 million for a service to an insured patient, that physician will receive a$1 million payment in the form of profit. This is in contrast, for example, to the situation when an insurer pays an individual$250,000 to a private physician to perform an operation. Without direct incentives to produce results, it is likely that physicians in these two types of arrangements will not see the value in producing high-quality services, because the incentive to produce high-quality services is not present.
In summary, the financial incentives for high-quality healthcare are different in the managed care system than they are in a fee-for-service system; and, as the costs of providing care rise in this model, the value of providing care to patients drops. Thus, as more insurers move into the managed care sector, the incentives for providing quality outcomes to patients become even more limited and the benefits of providing care to patients in this industry diminish. As a result, many healthcare providers, including the physicians themselves, are turning to alternatives for providing healthcare services, for which there have been few other choices.